Consumers say that smaller doses of a popular weight-loss drug eased side effects and improved their health Telehealth ...
The GLP-1 trend is changing the food landscape dramatically. Some sectors stand a chance to win, such as functional ...
The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.
MedPage Today on MSN
Food companies are targeting users of weight-loss drugs with 'GLP-1 friendly' labels
Both Conagra and Nestle got approval from the USDA's Food Safety and Inspection Service to use "GLP-1 Friendly" labels. The ...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
Everyday Health on MSN
Using GLP-1s for Obesity During Menopause: Benefits and Risks
Learn how GLP-1 medications support weight loss and heart health in perimenopause and postmenopause, plus get tips for ...
GLP-1 weight-loss drugs have already seen massive success in the US. While they've made some headway into the European market ...
GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...
Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...
In a new trial, people who switched to the experimental daily GLP-1 pill orforglipron were able to keep off most of the weight they had lost taking Wegovy or Zepbound. People who switched from Wegovy ...
GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence suggests.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results